DVC1-0101 to treat peripheral arterial disease: A phase I/IIa open-label dose-escalation clinical trial

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 707-714

  Yonemitsu, Yoshikazu ^a   Matsumoto, Takuya ^b   Itoh, Hiroyuki ^b   Okazaki, Jin ^b   Uchiyama, Makiko ^c   Yoshida, Kumi ^a   Onimaru, Mitsuho ^b   Onohara, Toshihiro ^b   Inoguchi, Hiroyuki ^b   Kyuragi, Ryoichi ^a,b   Shimokawa, Mototsugu ^c   Ban, Hiroshi ^d   Tanaka, Michiko ^a,c   Inoue, Makoto ^d   Shu, Tsugumine ^d   Hasegawa, Mamoru ^d   Nakanishi, Yoichi ^c   Maehara, Yoshihiko ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DVC 1 0101; FIBROBLAST GROWTH FACTOR 2; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADULT; AGED; ANEMIA; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECUBITUS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROBLAST GROWTH FACTOR 2 GENE; FOLLOW UP; GENE; GENE TRANSFER; HEMAGGLUTINATION TEST; HUMAN; HYPOALBUMINEMIA; MALE; OPEN STUDY; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; TOE PRESSURE INDEX; TREATMENT DURATION; ULCER; VIRUS EXPRESSION; VIRUS PARTICLE;

SENDAI VIRUS;

EID: 84875230671     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.279     Document Type: Article

References (23)

1. Weitz, JI, Byrne, J, Clagett, GP, Farkouh, ME, Porter, JM, Sackett, DL et al. (1996). Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94: 3026-3049.
2. Takeshita, S, Zheng, LP, Brogi, E, Kearney, M, Pu, LQ, Bunting, S et al. (1994). Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93: 662-670.
3. Lazarous, DF, Unger, EF, Epstein, SE, Stine, A, Arevalo, JL, Chew, EY et al. (2000). Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36: 1239-1244.
4. Lederman, RJ, Mendelsohn, FO, Anderson, RD, Saucedo, JF, Tenaglia, AN, Hermiller, JB et al.; TRAFFIC Investigators. (2002). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359: 2053-2058.
5. Rajagopalan, S, Mohler, ER 3rd, Lederman, RJ, Mendelsohn, FO, Saucedo, JF, Goldman, CK et al. (2003). Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938.
6. Comerota, AJ, Throm, RC, Miller, KA, Henry, T, Chronos, N, Laird, J et al. (2002). Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35: 930-936.
7. Nikol, S, Baumgartner, I, Van Belle, E, Diehm, C, Visoná, A, Capogrossi, MC et al.; TALISMAN 201 investigators. (2008). Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 16: 972-978.
8. Belch, J, Hiatt, WR, Baumgartner, I, Driver, IV, Nikol, S, Norgren, L et al.; TAMARIS Committees and Investigators. (2011). Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377: 1929-1937.
9. Yonemitsu, Y, Kitson, C, Ferrari, S, Farley, R, Griesenbach, U, Judd, D et al. (2000). Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18: 970-973.
10. Masaki, I, Yonemitsu, Y, Yamashita, A, Sata, S, Tanii, M, Komori, K et al. (2002). Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90: 966-973.
11. Onimaru, M, Yonemitsu, Y, Tanii, M, Nakagawa, K, Masaki, I, Okano, S et al. (2002). Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 91: 923-930.
12. Tsutsumi, N, Yonemitsu, Y, Shikada, Y, Onimaru, M, Tanii, M, Okano, S et al. (2004). Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ Res 94: 1186-1194.
13. Kubo, H, Cao, R, Brakenhielm, E, Mäkinen, T, Cao, Y and Alitalo, K (2002). Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 99: 8868-8873.
14. Onimaru, M, Yonemitsu, Y, Fujii, T, Tanii, M, Nakano, T, Nakagawa, K et al. (2009). VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. Am J Physiol Heart Circ Physiol 297: H1685-H1696.
15. Fujii, T, Yonemitsu, Y, Onimaru, M, Tanii, M, Nakano, T, Egashira, K et al. (2006). Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol 26: 2483-2489.
16. Li, HO, Zhu, YF, Asakawa, M, Kuma, H, Hirata, T, Ueda, Y et al. (2000). A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 74: 6564-6569.
17. Ikeda, Y, Yonemitsu, Y, Sakamoto, T, Ishibashi, T, Ueno, H, Kato, A et al. (2002). Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure. Exp Eye Res 75: 39-48.
18. Shoji, T, Yonemitsu, Y, Komori, K, Tanii, M, Itoh, H, Sata, S et al. (2003). Intramuscular gene transfer of FGF-2 attenuates endothelial dysfunction and inhibits intimal hyperplasia of vein grafts in poor-runoff limbs of rabbit. Am J Physiol Heart Circ Physiol 285: H173-H182.
19. Rutherford, RB, Baker, JD, Ernst, C, Johnston, KW, Porter, JM, Ahn, S et al. (1997). Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26: 517-538.
20. Grossman, PM, Mendelsohn, F, Henry, TD, Hermiller, JB, Litt, M, Saucedo, JF et al. (2007). Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 153: 874-880.
21. Regensteiner, JG, Ware, JE Jr, McCarthy, WJ, Zhang, P, Forbes, WP, Heckman, J et al. (2002). Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50: 1939-1946.
22. Labs, KH, Dormandy, JA, Jaeger, KA, Stuerzebecher, CS and Hiatt, WR (1999). Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 100: e75-e81.
23. Yonemitsu, Y and Kaneda, Y (1999). Hemagglutinating virus of Japan liposomemediated gene delivery to vascular cells. In: Baker, AH (ed.). Molecular Biology of Vascular Diseases. Methods in Molecular Medicine. Humana Press: Totowa, NJ. pp. 295-306.